Nunes G L, Thomas C N, Hanson S R, Barry J J, King S B, Scott N A
Andreas R. Gruentzig Cardiovascular Center, Emory University Hospital, Atlanta, Ga 30322, USA.
Circulation. 1995 Oct 1;92(7):1697-700. doi: 10.1161/01.cir.92.7.1697.
Systemic administration of heparin can decrease mortality and morbidity of acute ischemic coronary syndromes such as unstable angina and myocardial infarction. Hemorrhage is the major limiting factor in the clinical use of systemic heparin. The objective of the present study was to determine whether local delivery of heparin could inhibit platelet-dependent thrombosis without altering systemic bleeding parameters.
Hydrogel-coated angioplasty balloon catheters were dipped in a heparin solution, dried, and applied to a platelet-rich mural thrombus in a chronic ex vivo porcine arteriovenous shunt. 111In-labeled platelet deposition was quantified by gamma camera imaging. In a separate series of experiments, 3H-heparin was used to estimate the amount of heparin delivered to the thrombus with the coated balloon. Systemic heparin administration produced a dose-dependent decrease in platelet-dependent thrombus formation that was maximal at 200 units/kg. Bleeding times and activated partial thromboplastin times were prolonged at this dose. An equal inhibition of thrombus formation was achieved after the coated balloon was dipped in a heparin solution (10,000 units/mL) and deployed at the mural thrombus. In contrast to systemic heparin administration, there was no alteration in bleeding parameters associated with local heparin delivery. The estimated amount of heparin delivered with the coated balloon was 40 units.
Local delivery of heparin in amounts sufficient to inhibit platelet-dependent thrombosis can be accomplished with a hydrogel-coated coronary angioplasty balloon catheter. Local heparin delivery can inhibit thrombus formation in amounts that are several orders of magnitude lower than the required systemic dose. Local delivery of heparin was not associated with prolongation of bleeding parameters.
全身性给予肝素可降低急性缺血性冠状动脉综合征(如不稳定型心绞痛和心肌梗死)的死亡率和发病率。出血是全身性肝素临床应用中的主要限制因素。本研究的目的是确定局部给予肝素是否能抑制血小板依赖性血栓形成而不改变全身出血参数。
将水凝胶涂层的血管成形术球囊导管浸入肝素溶液中,干燥后应用于慢性体外猪动静脉分流术中富含血小板的壁血栓。通过γ相机成像对111In标记的血小板沉积进行定量。在另一系列实验中,使用3H-肝素估计用涂层球囊输送至血栓的肝素量。全身性给予肝素使血小板依赖性血栓形成呈剂量依赖性降低,在200单位/千克时达到最大效果。在此剂量下,出血时间和活化部分凝血活酶时间延长。将涂层球囊浸入肝素溶液(10000单位/毫升)并部署在壁血栓处后,血栓形成受到同等程度的抑制。与全身性给予肝素不同,局部给予肝素未改变相关的出血参数。涂层球囊输送的肝素估计量为40单位。
使用水凝胶涂层的冠状动脉血管成形术球囊导管可实现足以抑制血小板依赖性血栓形成的肝素局部输送。局部肝素输送可抑制血栓形成,所需剂量比全身给药剂量低几个数量级。局部给予肝素与出血参数延长无关。